asthma
1nhaler receives £1.5m in funding to develop new cardboard inhaler
November 19, 2025Research and Development 1nhaler, asthma
1nhaler, a Scotland-based developer of drug delivery devices, has received £1.5m in seed funding for the development of its new …
GSK shares positive results from phase 3 asthma trials
May 21, 2024Research and Development Asthma & COPD, GSK, asthma, clinical trial
GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment
June 22, 2023Research and Development Asthma & COPD, Beclu, Lupin Healthcare, asthma, carbon neutral, inhaler
UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon neutral pressurised metered dose inhalers …
Asthma drug Dupixent sees positive results in child trials
May 18, 2021Manufacturing and Production FDA, asthma
Data presented at the 2021 American Thoracic Society International Conference from a Phase III trial of Dupixent (dupilumab) in children …
AstraZeneca and Amgen asthma drug shows positive results in Phase III trial
May 13, 2021Amgen, AstraZeneca, asthma, asthma treatment, pharma, pharma news, severe asthma
AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority across all primary and secondary …
GSK starts Phase III study for severe asthma treatment
March 18, 2021GSK, asthma, phase III
GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating …
NICE recommends GSK’s Nucala for more asthma patients
December 18, 2020Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab
NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …
Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma
September 8, 2020Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma
New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …
US approves new generic to treat people suffering from respiratory conditions
August 25, 2020Manufacturing and Production asthma, inhaler
The FDA has granted Lupin Ltd approval for their generic version of ProAir, which is used to prevent asthma symptoms …
AstraZeneca’s Fasenra has strong Phase 3 showing in severe eosinophilic asthma
August 6, 2020Research and Development AstraZeneca, Fasenra, asthma
AstraZeneca took the opportunity at the American Thoracic Society 2020 Virtual International Conference to unveil positive new Phase 3b data …
Study launched to assess if asthma treatment ciclesonide can treat COVID-19
June 18, 2020Business Services COVID-19, asthma, corona, coronavirus
Researchers at the University of Buffalo have launched a study to see if the steroid treatment ciclesonide could be effective …
The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns
March 10, 2020Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology
The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
Novartis abandons asthma drug after Phase 3 trial results
December 17, 2019Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d
Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …
